Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734A polymorphisms of human CYP1A2.

Han XM, Ou-Yang DS, Lu PX, Jiang CH, Shu Y, Chen XP, Tan ZR, Zhou HH.

Pharmacogenetics. 2001 Jul;11(5):429-35.

PMID:
11470995
2.

Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans.

Ghotbi R, Christensen M, Roh HK, Ingelman-Sundberg M, Aklillu E, Bertilsson L.

Eur J Clin Pharmacol. 2007 Jun;63(6):537-46. Epub 2007 Mar 17.

PMID:
17370067
3.

G-2964A and C734A genetic polymorphisms of CYP1A2 in Chinese population.

Han XM, Chen XP, Wu QN, Jiang CH, Zhou HH.

Acta Pharmacol Sin. 2000 Nov;21(11):1031-4.

4.

The G-113A polymorphism in CYP1A2 affects the caffeine metabolic ratio in a Chinese population.

Chen X, Wang L, Zhi L, Zhou G, Wang H, Zhang X, Hao B, Zhu Y, Cheng Z, He F.

Clin Pharmacol Ther. 2005 Sep;78(3):249-59.

PMID:
16153396
5.

Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine.

Sachse C, Brockmöller J, Bauer S, Roots I.

Br J Clin Pharmacol. 1999 Apr;47(4):445-9.

6.

Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population.

Gunes A, Ozbey G, Vural EH, Uluoglu C, Scordo MG, Zengil H, Dahl ML.

Pharmacogenomics. 2009 May;10(5):769-78. doi: 10.2217/pgs.09.22.

PMID:
19450128
7.

Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine.

Carrillo JA, Christensen M, Ramos SI, Alm C, Dahl ML, Benitez J, Bertilsson L.

Ther Drug Monit. 2000 Aug;22(4):409-17.

PMID:
10942180
8.

Influence of the genetic polymorphism in the 5'-noncoding region of the CYP1A2 gene on CYP1A2 phenotype and urinary mutagenicity in smokers.

Pavanello S, Pulliero A, Lupi S, Gregorio P, Clonfero E.

Mutat Res. 2005 Nov 10;587(1-2):59-66. Epub 2005 Sep 26.

PMID:
16188490
9.

Association of CYP1A2 genetic polymorphisms with hepatocellular carcinoma susceptibility: a case-control study in a high-risk region of China.

Chen X, Wang H, Xie W, Liang R, Wei Z, Zhi L, Zhang X, Hao B, Zhong S, Zhou G, Zhang L, Gao X, Zhu Y, He F.

Pharmacogenet Genomics. 2006 Mar;16(3):219-27.

PMID:
16495781
10.

Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2.

Han XM, Ouyang DS, Chen XP, Shu Y, Jiang CH, Tan ZR, Zhou HH.

Br J Clin Pharmacol. 2002 Nov;54(5):540-3.

11.

Detailed modelling of caffeine metabolism and examination of the CYP1A2 gene: lack of a polymorphism in CYP1A2 in Caucasians.

Welfare MR, Aitkin M, Bassendine MF, Daly AK.

Pharmacogenetics. 1999 Jun;9(3):367-75. Erratum in: Pharmacogenetics 1999 Dec;9(6):782.

PMID:
10471069
12.

Five caffeine metabolite ratios to measure tobacco-induced CYP1A2 activity and their relationships with urinary mutagenicity and urine flow.

Sinués B, Sáenz MA, Lanuza J, Bernal ML, Fanlo A, Juste JL, Mayayo E.

Cancer Epidemiol Biomarkers Prev. 1999 Feb;8(2):159-66.

13.

Association between common CYP1A2 polymorphisms and theophylline metabolism in non-smoking healthy volunteers.

Wang L, Hu Z, Deng X, Wang Y, Zhang Z, Cheng ZN.

Basic Clin Pharmacol Toxicol. 2013 Apr;112(4):257-63. doi: 10.1111/bcpt.12038. Epub 2012 Dec 20.

14.

Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes.

Djordjevic N, Ghotbi R, Bertilsson L, Jankovic S, Aklillu E.

Eur J Clin Pharmacol. 2008 Apr;64(4):381-5. Epub 2007 Dec 22.

PMID:
18157525
16.

The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement.

van der Weide J, Steijns LS, van Weelden MJ.

Pharmacogenetics. 2003 Mar;13(3):169-72.

PMID:
12618594
17.

Interaction between cytochrome P450 1A2 genetic polymorphism and cigarette smoking on the risk of hepatocellular carcinoma in a Japanese population.

Imaizumi T, Higaki Y, Hara M, Sakamoto T, Horita M, Mizuta T, Eguchi Y, Yasutake T, Ozaki I, Yamamoto K, Onohara S, Kawazoe S, Shigematsu H, Koizumi S, Kudo S, Tanaka K.

Carcinogenesis. 2009 Oct;30(10):1729-34. doi: 10.1093/carcin/bgp191. Epub 2009 Jul 30.

PMID:
19643819
18.
19.

CYP1A2 genetic polymorphisms and adenocarcinoma lung cancer risk in the Tunisian population.

B'chir F, Pavanello S, Knani J, Boughattas S, Arnaud MJ, Saguem S.

Life Sci. 2009 May 22;84(21-22):779-84. doi: 10.1016/j.lfs.2009.03.008. Epub 2009 Mar 28.

PMID:
19332078
20.

Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene.

Nakajima M, Yokoi T, Mizutani M, Shin S, Kadlubar FF, Kamataki T.

Cancer Epidemiol Biomarkers Prev. 1994 Jul-Aug;3(5):413-21.

Supplemental Content

Support Center